Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling
about
Rapamycin and mTOR kinase inhibitorsNVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomasThe Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal CancerPI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastomaTargeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?A frequent kinase domain mutation that changes the interaction between PI3K and the membraneThe p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitorsTherapeutic targeting of cancers with loss of PTEN function.In vitro models of cancer stem cells and clinical applicationsDifferential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagyThe critical role of Akt in cardiovascular functionGenomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFRPhosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancerPleckstrin homology domain of Akt kinase: a proof of principle for highly specific and effective non-enzymatic anti-cancer targetEnhancing the evaluation of PI3K inhibitors through 3D melanoma models.IDEA: Integrated Drug Expression Analysis-Integration of Gene Expression and Clinical Data for the Identification of Therapeutic Candidates.Proteomic analysis of phosphoproteins sensitive to a phosphatidylinositol 3-kinase inhibitor, ZSTK474, by using SELDI-TOF MSInhibition of PI3K by PX-866 prevents transforming growth factor-alpha-induced pulmonary fibrosis.Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug designZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.The PIK3CA gene as a mutated target for cancer therapy.Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical developmentIdentification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.Small-molecule inhibitors of the PI3K signaling networkInvestigational agents in development for the treatment of ovarian cancerThe PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.Synthesis of 1,2,4-triazines and the triazinoisoquinolinedione DEF ring system of noelaquinone.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.PI3Kα inhibitors that inhibit metastasis.Phase II study of PX-866 in recurrent glioblastoma.The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenograftsThe skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signalingPIK3CA mutations predict recurrence in localized microsatellite stable colon cancerInsulin resistance induces posttranslational hepatic sortilin 1 degradation in mice.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Nisin ZP, a Bacteriocin and Food Preservative, Inhibits Head and Neck Cancer Tumorigenesis and Prolongs Survival.Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery.EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapyThe phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions.
P2860
Q24644623-7120582A-A662-4CC3-9D7C-89D8F78A0EDCQ24646237-15B71025-2634-414A-B4CE-17FD22725C2AQ26744721-5B9DD23B-0A99-41A4-9216-D972287B8977Q26766293-335E14F9-C0D6-4961-8599-A803D32C9376Q26775940-0513D2A0-FCA5-43B0-B333-D841C75E4427Q27657679-680A73E3-4016-44E0-90C2-D0326A2EDDE8Q27659013-53873E7F-7836-466D-B4C3-6333B5A99776Q27852764-D1B2E399-C2C6-4444-9243-908AECFCFB6BQ28076101-E0F862D9-BE96-44F0-8E45-195398231F84Q28081735-87507BEA-A58C-4E2A-A940-7F545087BB3FQ28083829-D33602D1-6067-4D38-BCCD-61AA0A247173Q28086993-33727743-1FA0-4C1D-BB70-BFC5428D6A72Q28472770-65073509-5BA0-414E-94F9-E92CF856DB04Q28485326-83880ED9-63AD-42D9-9991-6A33E8EA78B5Q30746265-CCCB4D31-A03B-4384-9DD5-3A6B145F7DA0Q30990059-856F8491-2D6E-4C2C-8EB9-FCDE7D31160FQ33424100-4DB47657-6F73-4EB1-BE17-BE95428EC27BQ33597113-9578D162-0B7F-4BB6-971F-B684C8A54ECDQ33653223-8E63FCEA-62EC-4A7D-8082-0847281B5C5AQ33685931-A6EBC400-A5E9-4DEC-8964-39BFA748CB84Q33699378-B90F0DF2-A570-4462-BFAF-EDED81D24639Q33776641-33B8DE17-CFB5-434D-BE01-1960E8BE1CB2Q33853600-D0FD1221-D3DB-4CFE-BEBA-0877EC88FA2DQ33883982-A85CD331-83D7-438D-ABA1-7D6DE568BBDAQ33920800-86ED8ED2-CBAC-4FC5-B57F-7D5CAB0B6D48Q33937368-F50D9CAF-5620-4190-A487-CB4C1DA9B09BQ34219476-E6045623-FB5B-47AF-A25A-1C41119C7500Q34307356-B8D63B60-A7BF-4EE5-9D4B-B48A8C157758Q34345154-D6738650-45C4-42B6-87D0-54FA9A69EC6AQ34416746-71A764EE-EC2A-44E5-9AE1-5720BD8AC91CQ34458889-3024C966-2179-4440-B638-898968ADDB4DQ34524510-5282EFEF-1525-4230-9A86-EEE9E5752044Q34708815-E6997104-D532-439D-8DC9-075194EE5F06Q35236785-7F7C1988-65B0-408D-B955-1F8C353134C6Q35561045-1834EF1D-DD45-432D-8942-328C255E41F6Q35679353-6A1B9DEE-655C-4105-AA87-B662A260549AQ35680064-AAAA4BD7-BD1D-41C4-89F9-BC2EB3C04453Q35991577-549B9B02-76D9-44BA-B090-AFAD870DB554Q36103054-64C01411-054E-4F87-AF1B-5F0235B1C00EQ36150234-294C64DE-3E69-4B61-AC1F-FBDDCCDF0A3E
P2860
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling
description
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2004
@ast
scientific journal article
@en
vedecký článok (publikovaný 2004/07/01)
@sk
vědecký článek publikovaný v roce 2004
@cs
wetenschappelijk artikel (gepubliceerd op 2004/07/01)
@nl
wissenschaftlicher Artikel
@de
наукова стаття, опублікована в липні 2004
@uk
مقالة علمية (نشرت في يوليو 2004)
@ar
name
Molecular pharmacology and ant ...... hoinositide-3-kinase signaling
@ast
Molecular pharmacology and ant ...... hoinositide-3-kinase signaling
@en
Molecular pharmacology and ant ...... hoinositide-3-kinase signaling
@nl
type
label
Molecular pharmacology and ant ...... hoinositide-3-kinase signaling
@ast
Molecular pharmacology and ant ...... hoinositide-3-kinase signaling
@en
Molecular pharmacology and ant ...... hoinositide-3-kinase signaling
@nl
prefLabel
Molecular pharmacology and ant ...... hoinositide-3-kinase signaling
@ast
Molecular pharmacology and ant ...... hoinositide-3-kinase signaling
@en
Molecular pharmacology and ant ...... hoinositide-3-kinase signaling
@nl
P2093
P3181
P1476
Molecular pharmacology and ant ...... hoinositide-3-kinase signaling
@en
P2093
Daniel J Minion
Garth Powis
Gillian Paine-Murrieta
Lynn Kirkpatrick
Margareta I Berggren
Nathan T Ihle
Peter Wipf
Robert Abraham
Robert J Halter
Ryan Williams
P304
P3181
P577
2004-07-01T00:00:00Z